Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-Label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Dulanermin Administered Intravenously in Combination With Rituximab to Subjects With Follicular and Other Low-Grade, CD20+, B-Cell Non-Hodgkin's Lymphomas That Have Progressed Following Previous Rituximab Therapy

NCT00400764 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00400764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00400764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-Label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Dulanermin Administered Intravenously in Combination With Rituximab to Subjects With Follicular and Other Low-Grade, CD20+, B-Cell Non-Hodgkin's Lymphomas That Have Progressed Following Previous Rituximab Therapy
Lead sponsor
Genentech, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2006
Completion date
Not reported
Enrollment
72 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma